Hennion & Walsh Asset Management, Inc. Autolus Therapeutics PLC Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 259,980 shares of AUTL stock, worth $431,566. This represents 0.03% of its overall portfolio holdings.
Number of Shares
259,980Holding current value
$431,566% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding AUTL
# of Institutions
111Shares Held
130MCall Options Held
0Put Options Held
116K-
Blackstone Inc New York, NY20.5MShares$34 Million0.24% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$27.6 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT14.2MShares$23.6 Million1.47% of portfolio
-
Avoro Capital Advisors LLC New York, NY9.91MShares$16.5 Million0.34% of portfolio
-
Armistice Capital, LLC New York, NY9.2MShares$15.3 Million0.31% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $151M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...